SBIR/STTR Research Award
Not Available
Award amount
$207,803Program and phase
SBIR · Phase IAward year
2010Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- VM DISCOVERY, INC.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Not reported
- Solicitation number
- PHS2010-1
- Topic code
- NCI
Research abstract
Breast cancer is a devastating affliction in Western Society. It is of high interest to quantify the expression of HER2/neu (a growth factor receptor), the estrogen receptor (ER), and the progesterone receptor (PR) in breast cancer tumors since HER2/neu expression is associated with high malignancy and because HER2Ineu, and ER are targets for anti-breast cancer therapies (Herceptin and tamoxifen, respectively). The presence or absence of PR is also helpful in diagnosing the sensitivity of a tumor to tamoxifen, since PR expression is dependent upon ER activity. The assay will quantify the populations of cells expressing HER2/neu, ER, and PR in the tumor sections obtained from biopsy material or surgical resection
Technology keywords
Not reported
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Mini-reflectance confocal microscope (Mini-RCM) for aiding skin cancer diagnosis and treatment
- Development of small molecule therapeutics targeting AR-V7 for prostate cancer
- Decentralized Clinical Trial of Effectiveness of EnergyPoints App to Guide Acupressure Use for Fatigue and Sleep Disturbances in Cancer Survivors
- Optimized targeted radiotherapy of pancreatic cancer
- Adaptive imaging for pioneering multiplexed spatial profiling of tumors and tissues for cancer research and diagnosis